193 related articles for article (PubMed ID: 20920853)
1. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
Heinemann L; Khatami H; McKinnon R; Home P
Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
[TBL] [Abstract][Full Text] [Related]
2. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia-Overview, Evolution, and Regulations Assessment.
Bas TG; Oliu Castillo C
Biomed Res Int; 2016; 2016():5910403. PubMed ID: 27213153
[TBL] [Abstract][Full Text] [Related]
4. Ten years of biosimilar recombinant human growth hormone in Europe.
Saenger P
Drug Des Devel Ther; 2017; 11():1505-1507. PubMed ID: 28553081
[TBL] [Abstract][Full Text] [Related]
5. The emergence of biosimilar insulin preparations--a cause for concern?
Owens DR; Landgraf W; Schmidt A; Bretzel RG; Kuhlmann MK
Diabetes Technol Ther; 2012 Nov; 14(11):989-96. PubMed ID: 23046400
[TBL] [Abstract][Full Text] [Related]
6. Bridging the gap: The future of biosimilars regulations.
Jarab AS; Abu Heshmeh SR; Al Meslamani AZ
Hum Vaccin Immunother; 2024 Dec; 20(1):2362450. PubMed ID: 38887055
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure.
Stević I; Janković SM; Georgiev AM; Marinković V; Lakić D
Sci Rep; 2024 Apr; 14(1):9074. PubMed ID: 38643204
[TBL] [Abstract][Full Text] [Related]
8. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report.
Pasmooij AMG; Mol PGM; Bot JC; Leufkens HGM
Clin Pharmacol Ther; 2024 Jul; 116(1):64-71. PubMed ID: 38679943
[TBL] [Abstract][Full Text] [Related]
9. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.
Impicciatore P; Choonara I
Br J Clin Pharmacol; 1999 Jul; 48(1):15-8. PubMed ID: 10383554
[TBL] [Abstract][Full Text] [Related]
10. Future of the European Union regulatory network in the context of the uptake of new medicines.
Hoebert JM; Irs A; Mantel-Teeuwisse AK; Leufkens HG
Br J Clin Pharmacol; 2013 Jul; 76(1):1-6. PubMed ID: 23043328
[No Abstract] [Full Text] [Related]
11. Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
Egilman AC; Van de Wiele VL; Rome BN; Darrow JJ; Tu SS; Kesselheim AS; Sarpatwari A
JAMA Intern Med; 2023 Jan; 183(1):82-84. PubMed ID: 36441536
[TBL] [Abstract][Full Text] [Related]
12. The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency?
Szymański P; Bossano Prescott EI; Weidinger F
Eur Heart J; 2024 Jan; 45(1):7-9. PubMed ID: 37850604
[No Abstract] [Full Text] [Related]
13. Where is European Regulation 536/2014 Taking Us?
Fox AW
Pharmaceut Med; 2023 Sep; 37(5):343-347. PubMed ID: 37353716
[TBL] [Abstract][Full Text] [Related]
14. An Evaluation of Malaysian Regulatory Process for New Active Substances Approved in 2017 Using the OpERA Methodology.
Sani NM; McAuslane N; Kasbon SH; Ahmad R; Yusof FAM; Patel P
Ther Innov Regul Sci; 2020 Sep; 54(5):1215-1224. PubMed ID: 32865804
[TBL] [Abstract][Full Text] [Related]
15. Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019.
Alsamil AM; Gardarsdottir H; Leufkens HG; Egberts TC; Giezen TJ
Drug Discov Today; 2023 Oct; 28(10):103725. PubMed ID: 37487844
[TBL] [Abstract][Full Text] [Related]
16. A new approach to psychiatric drug approval in Europe.
Barbui C; Bighelli I
PLoS Med; 2013 Oct; 10(10):e1001530. PubMed ID: 24143137
[TBL] [Abstract][Full Text] [Related]
17. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
18. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilar medicines. Scientific and legal disputes].
Dorantes Calderón B; Montes Escalante IM
Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
